← Leaderboards
Mohammad Nasir Uddin
Emergent Biotechnologies Llc
$931,649
Attributed
$1,380,952
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $770K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,380,952 · 4
By mechanism
R43$1,380,952 · 4
Top collaborators
- Babbette Babbette Lamarca1 shared
- James W Larrick1 shared
- Bo Yu1 shared
Others in their field
Other Emerging Leaders on “Effective Therapy”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$69,114,853
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Yunda Huang · Fred Hutchinson Cancer Center$51,679,442
Research focus
Effective TherapyPre-ClinicalInnovationReceptorAnimal ModelDrug KineticsPregnancyToxic EffectHalf-LifeSignal TransductionAnimalsEdemaDoseMediatingMorbidity - Disease RateIn VivoImproved OutcomeLifeAntihypertensive AgentsHypertensionBindingIn Vitro ActivityAffectFetal
Grant awards (4)
Novel Pharmacological Treatment for Preeclampsia$385,272
R43 · FY2023 · HD · contact PI
Advancing a novel therapy for preeclampsia$385,000
R43 · FY2022 · HD
Novel therapy for preeclampsia$384,958
R43 · FY2022 · HD · contact PI
Anti-fibrotic therapy for primary sclerosing cholangitis$225,722
R43 · FY2019 · DK · contact PI